AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
MARICO.NS
ACCE-researched

Marico Limited (MARICO.NS) fair value

Consumer Defensive · Household & Personal Products · NSE · India
₹766.50-1.10%
Market cap ₹993.7BNext earnings 2026-11-02Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionMarico Limited (MARICO.NS)
Fair value
Not available
ACCE price target
₹740
Rating
Not rated
Horizon
12 months
ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ₹767 at the close on 23 Oct 2026, 12:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
57
out of 100
P/E
52.6x
forward 39.3x
1-year return
+5.8%
Dividend yield
0.52%

Marico Limited in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Marico makes Parachute coconut oil, Saffola edible oils and Parachute Advansed hair oils, plus Set Wet hair styling and a growing set of skin care brands sold mainly through Indian general trade. Its moat is distribution depth and brand recall in hair care and edible oils, which lets it hold a 43.9% gross margin and a 19.3% operating margin despite input-cost swings in copra and palm-linked oils. Revenue growth of 21.4% is strong for a household staples name, and management's push into premium and value-added hair and skin products is the main reason the mix should keep improving. At 39.8 times forward earnings against 53.2 times trailing, the market is already pricing in a sharp earnings rebound, so the case rests on whether margins hold while volumes keep growing. This is worth a deeper look to check whether the 21.4% growth is durable volume or mostly pricing and acquired brands.

AI-assisted·How I use AIWritten Oct 23, 2026
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
  • moderate
    Rich valuation multiples
    P/E of 53.2 and EV/EBITDA of 41.0 leave little room for earnings misses. Price trades 3.6% above the ACCE price target of ₹740.00.

AI research notes

AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-10-22 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 21.4% year over year, well ahead of the company's 11.7% average annual pace over five years.
  • Earnings beat expectations, with earnings per share of 4.85 against 4.45 expected, a surprise of 8.9%.
  • Analysts' mean price target of INR 957.37 sits 23.5% above the current share price.
Why it could disappoint
  • At a trailing P/E of 53.2x, the shares price in a lot of good news already.
  • Even on forward earnings the stock trades at 39.8x, leaving little room for disappointment.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where MARICO.NS's valuation models land
Price
₹766.50
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-2.4%
1 month
-7.9%
3 months
-10.4%
6 months
-2.1%
YTD
+0.8%
1 year
+5.8%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
22 Oct 2026, 16:00 CESTACCE price target₹740first publication₹775

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in INR. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full MARICO.NS page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth80Value14Quality85Momentum47Total57
Valuation
Trailing P/E
52.6x
Forward P/E
39.3x
PEG
2.15
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
no data
FCF yield
no data
ROIC
no data
Health and risk
Debt / equity
0.12
Dividend yield
0.52%
Beta
no data

Price

+5.6% · 1Y

Ask anything about MARICO.NS

Answered from Marico Limited fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 18.4x52.6xhigh 52.6x
Div yieldbetter than 0% of peers
low 0.5%0.5%high 5.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
MARICO.NS Marico Limited₹766.50--52.6x-8557
CLX Clorox Company (The) Common Stock$88.66$6732% above18.4x163.8%6441
8113.T Unicharm Corporation¥1005.00--27.3x8.3%6364
4911.T Shiseido Company, Limited¥3569.00----3.1%5266
GODREJCP.NS Godrej Consumer Products Limited₹860.20₹313175% above45.8x15.1%7548
PUIG.MC Puig Brands SA€19.29€1618% above18.7x15.6%7261
DABUR.NS Dabur India Limited₹368.00--32.7x-8551

Sector report card

Where MARICO.NS ranks against its sector peers on each metric.

Computing percentiles…